Skip to content

Silvia Monari

Division of Adult Psychiatry, Department of Psychiatry, University Hospitals of Geneva, 2, Chemin du Petit-Bel-Air, Thônex CH-1226, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.

2 papers in the library · 29 citations · publishing 2024-2025

Papers

Half a Century of Research on Posttraumatic Stress Disorder: A Scientometric Analysis.

Current neuropharmacology January 1, 2024 Michel Sabé, Chaomei Chen, Wissam El-Hage et al. 25 citations

A scientometric analysis of 42,170 publications on posttraumatic stress disorder (PTSD) from 1945 to 2022 identified four major research trends: war veterans and refugees, treatment of PTSD/neuroimaging, evidence syntheses, and somatic symptoms of PTSD. The largest cluster focused on evidence synthesis for genetic predisposition and environmental exposures leading to PTSD. War-related trauma research has shifted from battlefield in-person exposure to drone operator trauma and is being outpaced by civilian trauma research, including the COVID-19 pandemic, postpartum, and grief disorder. Recent trends show a burst in PTSD treatment research involving Mhealth, virtual reality, and psychedelic drugs. The USA dominates collaboration networks, with a recent surge of publications from China. Compared to other psychiatric disorders, there is a lack of high-quality randomized controlled trials for pharmacological and nonpharmacological treatments.

Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.

Asian journal of psychiatry June 26, 2025 Adi Sulstarova, Luise Scheuerlein, Silvia Monari et al. 4 citations

Psychedelic-induced psychosis is rare, occurring in less than 1% of users in controlled trials, but evidence on its treatment is limited. A systematic review of 93 cases from 1955 to 2024 found that LSD (47.3%) and MDMA (38.7%) were the most common substances involved, with an average patient age of 23.7 years and 88% male. Psychosis lasted about 1.8 weeks on average. Second-generation antipsychotics had a response rate of 91.3%, significantly higher than first-generation antipsychotics at 27%. Electroconvulsive therapy also showed a 91% response rate. Follow-up revealed 34% of patients later developed schizophrenia spectrum disorders and 20.4% bipolar disorder, though limited follow-up data constrain these findings.